Alterity Therapeutics (ASX:ATH) has dosed its first UK patient in a Phase 2 clinical trial of its ATH434 treatment for Multiple System Atrophy (MSA).

The trial will evaluate the effect of the drug on neuroimaging and protein biomarkers, as well as clinical endpoints to demonstrate efficacy, and assessments of safety and pharmacokinetics.

The trial is enrolling participants across sites in five countries.

ATH434 is designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration, which cause the failure of the autonomic nervous system and impaired movement.